Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 117

1.

HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden.

Tarján A, Dudás M, Wiessing L, Horváth G, Rusvai E, Tresó B, Csohán Á.

Int J Drug Policy. 2017 Mar;41:1-7. doi: 10.1016/j.drugpo.2016.11.006. Epub 2016 Dec 13.

PMID:
27984762
2.

Dandelion Taraxacum linearisquameum does not reflect soil metal content in urban localities.

Kováčik J, Dudáš M, Hedbavny J, Mártonfi P.

Environ Pollut. 2016 Nov;218:160-167. doi: 10.1016/j.envpol.2016.08.030. Epub 2016 Aug 24.

PMID:
27566846
3.

Two New Isomers of Palmityl-4-hydroxycinnamate from Flowers of Taraxacum Species.

Dudáš M, Vilková M, Béres T, Repcák M, Mártonfi P.

Nat Prod Commun. 2016 Jun;11(6):837-40.

PMID:
27534130
5.

Trends in HIV surveillance data in the EU/EEA, 2005 to 2014: new HIV diagnoses still increasing in men who have sex with men.

Pharris A, Quinten C, Tavoschi L, Spiteri G, Amato-Gauci AJ; ECDC HIV/AIDS Surveillance Network.

Euro Surveill. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30071. Erratum in: Euro Surveill. 2015;20(49). doi: 10.2807/1560-7917.ES.2015.20.49.30090.

6.

Characterisation of the large-scale production process of oyster mushroom (Pleurotus ostreatus) with the analysis of succession and spatial heterogeneity of lignocellulolytic enzyme activities.

Bánfi R, Pohner Z, Kovács J, Luzics S, Nagy A, Dudás M, Tanos P, Márialigeti K, Vajna B.

Fungal Biol. 2015 Dec;119(12):1354-1363. doi: 10.1016/j.funbio.2015.10.003. Epub 2015 Oct 22.

PMID:
26615756
7.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators.

N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.

8.

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group.

Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9.

PMID:
26268910
9.

Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance.

Cole MJ, Spiteri G, Jacobsson S, Pitt R, Grigorjev V, Unemo M; Euro-GASP Network.

BMC Infect Dis. 2015 Aug 11;15:321. doi: 10.1186/s12879-015-1013-x.

10.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

11.

Glycogen synthase kinase-3 (Gsk-3) plays a fundamental role in maintaining DNA methylation at imprinted loci in mouse embryonic stem cells.

Meredith GD, D'Ippolito A, Dudas M, Zeidner LC, Hostetter L, Faulds K, Arnold TH, Popkie AP, Doble BW, Marnellos G, Adams C, Wang Y, Phiel CJ.

Mol Biol Cell. 2015 Jun 1;26(11):2139-50. doi: 10.1091/mbc.E15-01-0013. Epub 2015 Apr 1.

12.

Paediatric leukaemia DNA methylation profiling using MBD enrichment and SOLiD sequencing on archival bone marrow smears.

Wong NC, Meredith GD, Marnellos G, Dudas M, Parkinson-Bates M, Halemba MS, Chatterton Z, Maksimovic J, Ashley DM, Mechinaud F, Craig JM, Saffery R.

Gigascience. 2015 Mar 18;4:11. doi: 10.1186/s13742-015-0050-0. eCollection 2015.

13.

Emerging Risks Due to New Injecting Patterns in Hungary During Austerity Times.

Tarján A, Dudás M, Gyarmathy VA, Rusvai E, Tresó B, Csohán Á.

Subst Use Misuse. 2015;50(7):848-58. doi: 10.3109/10826084.2015.978672. Epub 2015 Mar 16.

PMID:
25775136
14.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD; on behalf of the EDITION 3 study investigators.

Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.

15.

Risk factors for antimicrobial-resistant Neisseria gonorrhoeae in Europe.

Cole MJ, Spiteri G, Town K, Unemo M, Hoffmann S, Chisholm SA, Amato-Gauci AJ, van de Laar M, Ison CA; Euro-GASP Network.

Sex Transm Dis. 2014 Dec;41(12):723-9. doi: 10.1097/OLQ.0000000000000185.

PMID:
25581808
16.

Tripolar mitosis in human cells and embryos: occurrence, pathophysiology and medical implications.

Kalatova B, Jesenska R, Hlinka D, Dudas M.

Acta Histochem. 2015 Jan;117(1):111-25. doi: 10.1016/j.acthis.2014.11.009. Epub 2014 Dec 29. Review.

17.

The response to September 11: a disaster case study.

Crane MA, Levy-Carrick NC, Crowley L, Barnhart S, Dudas M, Onuoha U, Globina Y, Haile W, Shukla G, Ozbay F.

Ann Glob Health. 2014 Jul-Aug;80(4):320-31. doi: 10.1016/j.aogh.2014.08.215. Epub 2014 Nov 25. Review.

18.

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1.

PMID:
25190523
19.

Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis.

Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A.

Cancer Epidemiol. 2014 Aug;38(4):329-38. doi: 10.1016/j.canep.2014.06.002. Epub 2014 Jun 28. Review.

PMID:
24986642
20.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators.

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069

Supplemental Content

Loading ...
Support Center